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Abstract A series of prolinate and N-amidocarbothiolprolinate derivatives 14 
based on a fused pyrrole-3,4-dione core, bearing indole ring systems, are 15 
prepared from the corresponding amino acid and an aldehyde via thermal 16 
1,3-dipolar cycloaddition of azomethine ylides and condensation with 17 
benzoylisothiocyanate. Products are fully characterized by NMR, FT- IR, 18 
MS and an X-ray crystal structure. The prepared compounds are screened 19 
for their antibacterial activity against a range of Gram-positive and Gram-20 
negative bacteria and their antimycobacterial activity against M. tuberculosis 21 
H37Rv strain. In addition, two selected target compounds are evaluated for 22 
cytotoxicity, apoptosis, and anti-inflammatory effects on MCF-7 (breast 23 
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 2 
carcinoma) cell lines. The incorporation of indole ring and -C(O)NHC(S)- 1 
moiety resulted to be beneficial since the biological point of view. 2 
 3 
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 1 
Graphical Abstract 2 
 3 
 4 
Introduction 5 
Extensive studies to synthesize compounds possessing -C(O)NHC(S)-6 
moiety [1-4] and their metal complexes [5-7] have been focused on the 7 
preparation of variety of products with very attractive biological activity, for 8 
example, antitumoural agent [8] including a P53 activator Tenovin-1 [9] (e.g. 9 
1, Figure 1), as Nucleotide Binding Inhibitor (NBI) [10], microsomal 10 
epoxide hydrolase inhibitors [11], DNA-topoisomerase inhibitor activity 11 
[12] and some potentially important antifungal and antimicrobial activities 12 
[13-15]. Some pyrrolidine rings have been found to be bioactive in a range 13 
of biological properties [16] including antibacterial activity, virus inhibitors 14 
[17] such as HIV integrase inhibitors ZINC04885876 [18] (e.g. 2, Figure 1). 15 
In addition, the presence of an indole unit is known to play an important role 16 
in medicinal chemistry increasing the anti-cancer [19,20], antimicrobial, 17 
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anti-oxidant [21-23], antitubercular, anti-inflammatory activity, for example 1 
indomethacin (e.g. 3, Figure 1), and so forth [24]. So, the compounds bearing 2 
all these three pharmacophore moieties [-C(O)NHC(S)-, prolinate and indole 3 
heterocycle] are very attractive candidates to be tested in biological assais. 4 
We have previously reported the synthesis and some biological 5 
evaluation of pyrrolidine, aroylaminocarbo-N-thioylpyrrolidine [7,25], their 6 
several metal complexes [7], thiohydantoin [26] and pyrrolidine thiazole 7 
derivatives [27]. As a continuation of our work, and according to our 8 
experience, in this article we have prepared some new selected 9 
tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione structures incorporating 10 
-C(O)NHC(S)- moiety, prolinate and indole ring system in order to get 11 
potent anti(myco)bacterial agents and evaluate their cytotoxicity, apoptosis 12 
and anti-inflammatory effects on MCF-7 cell lines. 13 
 14 
 15 
 16 
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Figure 1. Representative examples of biologically important aroyl thiourea 1 
/ pyrrolidine and indole scaffolds. 2 
 3 
Results and Discussion 4 
Selected novel pyrrolidines 6a-d and aroylaminocarbo-N-thioylpyrrolidine 5 
7a-d were prepared. Prolinates 6 were obtained from the corresponding 6 
imines 4, derived from tryptophan methyl or ethyl ester and aldehydes, via 7 
thermal sequence imine-azomethine ylide-1,3-dipolar cycloaddition reaction 8 
using N-alkyl/aryl-maleimides 5 as dipolarophiles in refluxing toluene for 9 
36-48h (see experimental part). The prepared pyrrolidines were then 10 
condensed with benzoylisothiocyanate in dry acetonitrile at reflux for 24-36 11 
h affording the desired functionalized N-amidocarbothiolpyrrolidines 7a-d 12 
(Scheme 1), in good to excellent yields (73-90%). These reactions were 13 
performed in a larger scale (25 mmol) obtaining the same chemical yields. 14 
The relative configuration was unambiguously determined by 1H NMR, 13C 15 
NMR, FT- IR and MS and also by X-ray diffraction analysis of the 16 
crystalline structure 6a (see Supporting Information). 17 
 18 
 19 
 20 
 21 
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 2 
 3 
Scheme 1 4 
 5 
 6 
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 1 
Antibacterial Activity  2 
Anti-bacterial activity was investigated against Staphylococcus aureus 3 
(ATCC 25925), Bacillus subtilis (ATCC 6633), Aeromonas hydrophila 4 
(ATCC 95080), Escherichia coli (ATCC 25923) and Acinetobacter 5 
baumanii (ATCC 02026) which provided by the Refik Saydam Hıfzısıhha 6 
Institute. Ampicillin was used as a reference drug. The minimum inhibitory 7 
concentrations (MIC) values were determined by broth microdilution 8 
method in duplicate as recommended by the Clinical Laboratory Standards 9 
Institute [28]. Stock solutions were prepared by dissolving the compounds 10 
in DMSO and then diluting in Mueller-Hinton broth and Triptic soy broth 11 
and the test medium were prepared at concentrations of 500, 250, 125, 62.5, 12 
31.25, 15.62, 7.8, 3.9 and 1.9 μg/cm3. Effects of DMSO were controlled by 13 
inoculated broth supplement at the same solutions. The observed data on the 14 
inhibited growth of bacteria at (MIC) values are given in Table 1. 15 
The tested compounds 6a-d and 7a-d inhibited the growth of bacteria 16 
at (MIC) values in the range of 15.62-250 μg/cm3. The control, ampicillin, 17 
showed activity against the tested bacteria with a range of 0.9-125 μg/ cm3. 18 
The compounds 7a, 7b, 7d were found to show the highest activity against 19 
Aeromonas hydrophila (ATCC 95080) in MIC values of 15.62 µg/ cm3, and 20 
the compounds 6a, 6b, 6d and 7b, 7d showed better activity than ampicillin 21 
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 8 
against Acinetobacter baumannii (ATCC 02026) whereas the tested 1 
compounds 6a-d and 7a-d showed the lowest activity to other bacteria with 2 
the MIC values of 62.5- 250 µg/cm3 as indicated in Table 1. 3 
 4 
 5 
Table 1. The MIC values (μg/cm3) of the target compounds against the 6 
bacteria and M. tuberculosis H37Rv strain. 7 
 8 
 Staphyl
ococcus 
aureus 
(ATCC 
25925) 
Escherichi
a coli 
(ATCC 
25923) 
Acinetoba
cter 
baumannii 
(ATCC 
02026) 
Bacillus 
subtilis 
(ATCC 
6633) 
Aeromonas 
hydrophila 
(ATCC 
95080) 
M. 
tuberculosi
s H37Rv 
6a 125  62,5  31,25  125  31,25 62,5 
6b 62,5 62,5 31,25 125 31,25 125 
6c 250  250  125  250  250  62,5  
6d 62,5 62,5 31,25 125 31,25 125    
7a 62,5  62,5 62,5   125 15,62  7,81 
7b 62,5 62,5 31,25 125 15,62 7,81 
7c 250  250  125  125 250  3,90  
7d 62,5 62,5 31,25 125 15,62 15,62 
Ampicillin 31.25  15.62 125  0.9 31.25   
Isoniazid      0,2 and 1 
Ethambutol      5 and 10 
 9 
 10 
Anti-tuberculosis (TB) activity 11 
Anti-TB activity of the compounds was investigated according to literature 12 
method [29-30] utilizing Microplate Alamar Blue assay against M. 13 
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 9 
tuberculosis H37Rv which provided by the Refik Saydam National Public 1 
Health Agency, National Tuberculosis Reference Laboratory, Ankara, 2 
Turkey. 3 
The compounds 6a-d and 7a-d were screened and measured by means 4 
of MIC values (µg/cm3). Ethambutol (EMB) (Sigma E4630) and Isoniazid 5 
(INH) (Sigma I3377) were used as standard reference drugs and the results 6 
with MIC values are shown in Table 1. 7 
The tested compounds 6a-d, 7a-d exhibited anti-tuberculosis activity 8 
in the range of 3,90 -125 µg/cm3 suggesting that better MIC values when 9 
compared their antibacterial activity. Especially the compound 7c, possess –10 
Cl on the phenyl ring and –CO2Et moiety in the pyrrolidine ring, exhibited 11 
the highest activity against M. tuberculosis H37Rv strain (3.90 µg/cm3) even 12 
better activity than known reference drugs ethambutol and moderate activity 13 
when compared to isoniazid as known reference drug (Table 1). The 14 
compounds 7a, 7b and 7d showed moderate activity with the MIC values of 15 
7.81-15.62 µg/cm3, whereas the compounds 6a-6d showed the lowest 16 
activity with the MIC values of 62.5-125 µg/cm3.  17 
It is also important to note the incorporation of -C(O)NHC(S)- moiety 18 
resulted to be very beneficial in most cases.  19 
 20 
Biological evaluation on MCF-7 (breast carcinoma) cell lines 21 
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Two selected target compounds 6a and 7a were chosen to test their 1 
cytotoxicity and their effects on apoptosis and inflammation on the human 2 
breast cancer MCF-7 cells. 3 
 4 
Cytotoxicity 5 
Cell proliferation experiments were carried out using the xCELLigence 6 
RTCA DP instrument, in a humidified incubator at 37°C and 5% CO2 7 
according to the instructions of the supplier (Roche Applied Science and 8 
ACEA Biosciences). Cell suspension was seeded into the wells of E-plates 9 
(30,000 cells/well) [31].  Impedance value of each well was automatically 10 
monitored by the xCELLigence system or duration of 24 h and was 11 
expressed as a cell index (CI) value. At the beginning of the log phase 7a 12 
and 6a were added into the wells in 10, 20, 50, 100 µM concentrations. 13 
0.01% DMSO was used as a vehicle group.  Cells were grown with complete 14 
medium was used as control while 0.01% DMSO was used as a vehicle 15 
group. Three replicates of each group were used, and the experiment was 16 
ended at 100th h. All data have been recorded by the supplied RTCA software 17 
(version 1.2.1). 18 
Treatment the cells with 7a at 10 and 20 μM caused a significant increase of 19 
cell index whereas at 50 and 100 µM caused a significant drop in the cell 20 
index (Figure 2) and IC50 value of 7a was calculated as 30 µM. In addition, 21 
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treatment the cells with 6a at 10, 20 and 50 μM caused a significant increase 1 
of cell index whereas at 100 µM caused a significant inhibition (50%) in the 2 
cell index (Figure 3). 3 
 4 
Cell Culture  5 
MCF-7 cells (Cat. No: 00092502 Şap Enstitüsü Ankara, TURKEY) were 6 
grown on six-well plate petri dishes containing RPMI 1640 medium 7 
supplemented with %10 fetal bovine serum (FBS), %1 L-Glutamine, %1 8 
Penicillin-streptomycin and amphotericin-B as monolayer culture until they 9 
reached 50-60% confluence. 10 
 11 
Biochemical analysis 12 
In this study four groups were included. MCF-7 cells were incubated with 13 
complete medium (n=2) as control group which have no treatment. For the 14 
experimental groups, they were treated either with 0.01% DMSO (DMSO 15 
Group) or 30 µM 7a (7a Group) or 100 µM 6a (6a Group) in complete 16 
medium (n=2). After 24 and 48 h of treatment, cells were harvested and re-17 
suspended in 100 µl of D-PBS for the biochemical investigations. 18 
 19 
Apoptosis 20 
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Caspase -8 and -9 enzyme activities were evaluated as apoptotic markers 1 
[32]. For the determination of protein, MCF-7 cells were homogenized in 2 
lysis buffer by 10 min of centrifugation at 14,000 × g at 4 ◦C. Protein levels 3 
were evaluated respect to Lowry assay [33] in cytosolic extract. Caspase-8, 4 
caspase-9 and COX-2 enzyme activities were analyzed in supernatants. 5 
Caspase-8 and -9 enzyme activities were evaluated by using Caspase-8 6 
Colorimetric Assay Kit (BioVision Research Product, Mountain View, CA, 7 
USA) and Caspase-9 Colorimetric Assay Kit (BioVision Research Product, 8 
Mountain View, CA, USA), respectively. All enzymatic activities were 9 
evaluated respect to the manufacturer's instructions. Spectrophotometric 10 
methods were based on finding out chromophore pNA after splitting from 11 
the labeled substrate. Caspase-8 and -9 enzyme activities were quantified by 12 
free pNA cleavage from IETD-pNA and LEHD-pNA respectively. 13 
  There was no statistically significant difference between the groups in 14 
caspase-8 enzyme activity which is the initiator caspase of death receptor 15 
induced (extrinsic) pathway of apoptosis (Figure 4). These results can be 16 
considered that the evaluated compounds (6a,7a) have no effects on this 17 
extrinsic pathway. Caspase-9 which is the apical caspase of the 18 
mitochondrial pathway and is recruited to in response to signals originating 19 
from inside the cell. There was a statistically significant increase in the 6a 20 
48 h group compared with the DMSO 48 h group, but in caspase activity. 21 
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Caspase-9 was also increased in 7a 48 h group compared with the DMSO 48 1 
h group, but it was not significant. 6a increased apoptosis by altering 2 
caspase-9 enzyme activity, suggesting that it has potential effect on the 3 
mitochondrial (intrinsic) pathway (Figure 4). 4 
 5 
Inflammation 6 
COX2 levels were measured to assess inflammation in MCF-7 cells. COX2 7 
enzyme activity was assayed respect to the manufacturer’s guidance 8 
(Shanghai Sunred Biological Technology Co., Ltd. Assay kit). The results 9 
were stated in U/mg protein. 10 
COX2 levels decreased statistically significant in 6a 24h group 11 
compared with the control 24h groups (Figure 5). COX1 and COX2 mediate 12 
the tissue repair process in the alimentary tract and take part in roles in tumor 13 
development at these sites [34].  COX2 is found over expressed in many 14 
cancer types [35].  Reduction of COX2 level of 6a in MCF-7 cell lines is an 15 
important evidence for the prevention of inflammation in tumor 16 
development. 17 
Statistical analysis 18 
Descriptive statistics (mean ± standard deviation) were calculated in each 19 
group for all parameters. For the comparison of groups, one-way 20 
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ANOVA (ANalysis of VAriance) with post-hoc Tukey was used. p<0.05 1 
was estimated to be statistically signiﬁcant. 2 
 3 
 4 
Figure 2: Red: Control, Green: DMSO group, Navy blue: 7a at 10 µM, Pink: 5 
7a at 20 µM, Turquoise: 7a at 50 µM, Purple: 7a at 100 µM 6 
 7 
 8 
 9 
Figure 3: Red: Control, Green: DMSO group, Navy blue: 6a at 10 µM, Pink: 10 
6a at 20 µM, Turquoise: 6a at 50 µM, Purple: 6a at 100 µM. 11 
 12 
 13 
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 1 
Figure 4. Effect of compounds 7a and 6a on Caspase 8 and on Caspase 9 on 2 
MCF-7 cell line.  3 
** p<0.05 vs.  DMSO 48 h. 4 
 5 
 6 
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Figure 5. Effect of compounds 7a and 6a on COX2 on MCF-7 cell line. # 1 
p<0.05 vs. Control 24h. 2 
 3 
Atomic arrangement-activity studies 4 
Although the mode of action of these molecules with the biological targets 5 
is unknown at the moment, it is worth to furthering this work by modifying 6 
such these substrates on the aspect of structural diversity and subsequently 7 
testing of other biological activities. Structure-activity relationship (SAR) is 8 
very risky due to small amount of structured tested. However, a reasonable 9 
prediction can be attempted after analyzing the minimum energy for 10 
compounds 7b (this work) and 8 [27] (Figure 6). The rigid core fused 11 
bicyclic entity in 7b is very important to get the free accessible sulfur atom 12 
able to interact as nucleophile with the natural target. However, in the 13 
absence of this rigid skeleton in compound 8, the sulfur atom is flanked by 14 
two phenyl groups avoiding a favorable approach to the living media. Two 15 
more details need to be pointed. The presence of aromatic rings can attract 16 
another π-clouds favoring specific approaches in both examples and the NH 17 
bond of the indole would promote another important hydrogen bond with a 18 
nucleophilic moiety of the biological target. In fact, a hydrogen bond can be 19 
formed between this indole-NH and the ester group in both molecules 7b and 20 
8 (Figure 6).   21 
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 1 
 2 
                                7b                                                                 8 3 
                        4 
Figure 6. MM2 minimal energy calculations [36] of compounds 7b and 8.  5 
 6 
 7 
Conclusion 8 
We have described synthesis of four novel 6a-d, 7a-d pyrrolidine and 9 
aminocarbothiol pyrrolidine derivatives based on pyrrole-3,4-dione, bearing 10 
indole ring system in good yields. The prepared compounds were screened 11 
for their anti(myco)bacterial activity against a range of bacteria and M. 12 
tuberculosis H37Rv strain. The screened compounds showed moderate 13 
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antibacterial activity against various bacteria strains whereas showed better 1 
anti-TB activity against M. tuberculosis H37Rv strain. In general, better 2 
bactericide activity was observed than those previously reported by our 3 
group. The obtained results displayed that these target compounds can be 4 
considered as potential anti(myco)bacterial activity agent, especially anti 5 
tuberculosis agent (e.g. 7a, 7b and 7c). The compound 7c exhibited higher 6 
activity against M. tuberculosis H37Rv strain in 3.90 µg/ cm3 values and 7 
show even better activity than known reference drugs ethambutol and 8 
moderate activity when compared to isoniazid as known reference drugs. 9 
Moreover, two selected target compounds 6a and 7a were evaluated for 10 
cytotoxicity, apoptosis and anti-inflammatory effects on MCF-7 cell lines. 11 
In addition, the tested compounds 6a and 7a reflect moderate activity against 12 
some of the used tumor cells which can be consider as potential bioactive to 13 
possible anti-carcinogenic properties on MCF-7 cell lines. It is also 14 
important to note that the incorporation of indole ring and -C(O)NHC(S)- 15 
moiety resulted to be crucial for the increment of activity since the biological 16 
point of view, so they can consider promising candidates for antitumor 17 
agents. As tentative proposal the sulfur atom can play a crucial role in the 18 
effective interaction with the living target in order to get the experimentally 19 
observed inhibition of the cell/bacteria. 20 
 21 
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Experimental  1 
All chemicals were purchased from Merck or Sigma-Aldrich and used 2 
without further purification. Melting points were determined on a Stuart 3 
SMP3 hot stage apparatus and are uncorrected. The structurally most 4 
important peaks of the IR spectra (Perkin-Elmer FT-IR using horizontal 5 
ATR) are listed and wave numbers are given in cm-1. Nuclear magnetic 6 
resonance spectra were determined on a Bruker Ultra Shield Plus Biospin 7 
GmbH 400 MHz spectrometer. Chemical shifts are reported in parts per 8 
million (δ) downfield from tetramethylsilane as internal standard. Spectra 9 
were determined in deuterated chloroform or DMSO-d6 as stated. The 10 
following abbreviations are used; s = singlet, d = doublet, t = triplet, q = 11 
quartet, m = multiplet and br s = broad singlet. Flash column 12 
chromatography was performed using silica gel 60. Mass spectra were 13 
recorded on an Agilent LC/MSD, Agilent 6460 Triple Quad LC/MS/MS 14 
mass spectrometer. The X-ray crystal structure data were collected on Bruker 15 
APEX-II CCD model X-ray diffractometer. Flash column chromatography 16 
was performed using silica gel 60 (230-400 mesh). High-resolution mass 17 
spectra (HRMS) were measured in a Finnigan MAT 95S using ESI. 18 
 19 
General Procedure for the synthesis of bicyclic pyrrolidines 6 20 
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The pyrrolidine derivatives 6a-d prepared by adaption of literature 1 
procedures [4,7,15,27]. Thus, aldehydes (1,1 mmol) in 10 cm3 were added to 2 
L-tryptophan methyl/ethyl esters (1mmol) in 20 cm3 dry DCM to form 3 
corresponding imines 4. Then, N-maleimides (1mmol) in dry toluene were 4 
added to imine solution (1 mmol). The reaction mixture was stirred under 5 
reflux for 36-48 h. After completion of the reaction by monitoring TLC, the 6 
reaction mixture was evaporated and crystallized from ether-hexane. Rf 7 
values for each compounds 6a-d were calculated in (Et2O: hexane, 2:1). 8 
 9 
(1S,3R,3aS,6aR)-methyl 1-((1H-indol-2-yl)methyl)-3-(4-chlorophenyl)-5-10 
ethyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (6a, 11 
C25H24ClN3O4) 12 
Crystallized from Et2O: hexane as colorless prisms. Yield 58 %: m.p.: 237-13 
239 ºC. Rf : 0.20, 
1H NMR (400 MHz, DMSO):   = 11.00 (br s, 1H, NH), 14 
7.57-6.95 (m, 9H, Ar-H), 5.02 (dd, 1H, J= 4.68 Hz, J= 9.4 Hz, 5-H), 3.72 15 
(dd, 1H, J= 8.38 Hz, J= 7.52 Hz, 4-H), 3.68 (s, 3H, OCH3), 3.60 (dd, 1H,  J= 16 
7.46 Hz, J= 1.38 Hz, 3-H), 3.43 (d, 1H, J= 14.6 Hz, 6-H), 3.30 (d, 1H, J= 17 
14.56 Hz,  6- H'),  3.25-3.13 (m, 2H, CH2CH3), 2.44 (d, 1H, J= 3.52 Hz, N-18 
H), 0.91 (t, 3H, J= 7.16 Hz, CH2CH3) ppm; 
13C NMR (100 MHz, DMSO): 19 
= 175.79 (C=O), 174.6 (C=O), 171.6 (C=O), 138.2, 135.9, 131.8, 129.2 (2 20 
C), 127.8 (2 C), 127.6, 124.4, 121.0, 118.6, 118.0, 111.5, 107.9, 70.2, 58.8, 21 
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53.4, 51.5, 48.5, 32.9, 30.3, 12.7 ppm; IR =  3339, 2981, 2944, 2840, 1774 1 
(C=O), 1739 (C=O), 1683 (C=O), 744 cm-1, m/z = 466.3 ([M+H]+, 100): 2 
468.3 ([M+H]+, 35); HRMS (ES): C25H24ClN3O4 calc. ([M+H]
+ 465.1455, 3 
found 465.1449. 4 
 5 
 (1S,3R,3aS,6aR)-ethyl 1-((1H-indol-2-yl)methyl)-3-(4-methoxyphenyl)-4,6-6 
dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (6b, 7 
C31H29N3O5) 8 
Crystallized from Et2O: hexane as colorless prisms. Yield 87 %: m.p.: 268-9 
270 ºC (decomp.),  Rf : 0.24, 
1H NMR (400 MHz, DMSO):   = 11.01 (bs, 10 
1H, NH), 7.60-6.89 (m, 14H, Ar-H), 5.11 (dd, 1H, J = 9.38 Hz, 4.8 Hz, 5-11 
H), 4.13-4.04 (m, 2H, CH2CH3), 3.88 (dd,1H, J = 9.34 Hz, 7.68 Hz, 4-H), 12 
3.77 (dd, 1H, J = 7.56 Hz, 1,44 Hz, 3-H), 3.74 (s. 3H, OCH3),  3.44 (d, 1H, 13 
J = 14.56 Hz, 6-H), 3.34 (d, 1H, J = 14.50 Hz, 6-H'), 2.44 (d, 1H, J = 4.68 14 
Hz, N-H), 1.25 (t, 3H, J = 7.12 Hz, CH2CH3) ppm; 
13C NMR (100 MHz, 15 
DMSO): = 175.4 (C=O), 174.2 (C=O), 171.3 (C=O), 158.7, 136.9, 132.2, 16 
130.8, 128.8 (2 C), 128.5 (2 C), 128.2, 127.7, 126.7 (2 C), 124.3, 121.0, 17 
120.2, 118.5, 118.1, 113.3, 111.5, 108.0, 70.4, 60.4, 59.5, 55.0, 54.1, 49.1, 18 
30.2, 13.9 ppm ; IR  = 3356, 3067, 2995, 1772, 1708 cm-1, MS (ESI)   m/z 19 
= 524.3 ([M+H]+, 100). 20 
 21 
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(1S,3R,3aS,6aR)-ethyl 1-((1H-indol-2-yl)methyl)-3-(4-chlorophenyl)-5-1 
methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (6c, 2 
C25H24ClN3O4) 3 
 Crystallized from Et2O: hexane as colorless prisms. Yield 76 %; m.p.: 213-4 
215 ºC (decomp.),  Rf : 0.20, 
1H NMR (400 MHz, CDCl3):   = 8.25 (bs, 1H, 5 
NH), 7.56 (d, 1H, J = 7.88 Hz, Ar-H), 7.25-6.96 (m, 8H, Ar-H), 4.85 (dd, 6 
1H, J = 9.1 Hz, 3.60 Hz, 5-H), 4.33-4.17 (m, 2H, CH2CH3), 3.61 (d, 1H, J = 7 
14.68 Hz, 6-H), 3.55 (dd, 1H, J = 9.0 Hz, 7.66 Hz, 4-H), 3.44 (d, 1H, J = 8 
7.48 Hz, 3-H), 3.24 (d, 1H, J = 14.64 Hz, 6-H'), 2.79 (s, 3H, NCH3), 2.50 (d, 9 
1H, J = 3.16 Hz, N-H), 1.34 (t, 3H, J = 7.16 Hz, CH2CH3) ppm; 
13C NMR 10 
(100 MHz, CDCl3): = 175.7 (C=O), 174.7 (C=O), 171.6 (C=O), 137.8, 11 
136.4, 135.9, 130.0, 128.6 (3C), 126.1, 123.2, 122.4, 119.9, 118.2, 111.5, 12 
109.2, 71.1, 61.7, 60.6, 54.0, 49.5, 24.9, 21.4, 14.1 ppm; IR:  =  3324,  13 
2959, 1777, 1725, 1698, 1430 1282, 1198, 1091, 1012,785, 740 cm-1 , MS 14 
(ESI) m/z = 466.2 ([M+H]+, 100): 468,2 ([M+H]+, 35); HRMS (ES): 15 
C25H24ClN3O4 calc. ([M+H]
+ 465.1455, found 465.1449. 16 
 17 
1S,3R,3aS,6aR)-ethyl 1-((1H-indol-2-yl)methyl)-3-(4-methoxyphenyl)-5-18 
methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (6d, 19 
C26H27N3O5) 20 
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Crystallized from Et2O: hexane as colorless prisms. Yield 75 %; m.p.: 185-1 
187 ºC,  Rf : 0.16, 
1H NMR (400 MHz, DMSO):   = 8.19 (s, 1H, NH), 7.59 2 
(d, 1H, J = 7.88 Hz, Ar-H), 7.25-6.80 (m, 8H, Ar-H), 4.85 (dd, 1H, J = 9.06 3 
Hz, 4.76 Hz, 5-H), 4.33-4.16 (m, 2H,CH2CH3), 3.75 (s, 3H, OCH3), 3.59 (d, 4 
1H, J = 14.56 Hz, 6-H), 3.53 (dd, 1H, J = 9.00 Hz, 7.52 Hz, 4-H), 3.45 (d, 5 
1H, J = 7.44 Hz, 3-H), 3.26 (d, 1H, J = 14.64 Hz, 6-H'), 2.80 (s, 3H, NCH3), 6 
2.55 (d, 1H, J = 4.52 Hz, N-H), 1.32 (t, 3H, J = 7.16 Hz, CH2CH3) ppm; 
13C 7 
NMR (100 MHz, DMSO): = 175.9 (C=O), 175.1 (C=O), 171.7 (C=O), 8 
159.5, 136.9, 129.8, 128.3 (2 C), 127.9, 123.2, 122.2, 119.8, 118.3, 113.8, (2 9 
C),  111.3, 109.5, 71.0, 61.6, 61.0, 55.2, 54.3, 49.8, 30.8, 24.9, 14.1 ppm; IR 10 
 = 3414, 3342, 2981, 1780, 1727 cm-1, MS (ESI)   m/z = 462.3 ([M+H]+, 11 
100). 12 
 13 
General Procedure for the synthesis of bicyclic benzoylaminocarbo-N-thiol-14 
pyrrolidines 7 15 
Bicyclic benzoylaminocarbo-N-thioylpyrrolidines 7a-d were prepared by 16 
adaption of literature procedures [4,7,15,27]. Thus, to a stirred solution of 17 
pyrrolidine (1.2 mmol) in 25 cm3 dry acetonitrile was added a solution of 18 
benzoyl isothiocyanate (1.22 mmol) in 15 cm3 of dry acetonitrile in 19 
dropwise. The resulting mixture was stirred at reflux for appropriate time 20 
(24-36 h) monitoring by TLC. After completion of the reaction, the solvent 21 
MCCM_Template_Vers 4   May 2014    
 24 
removed and purified by flash chromatography. Rf values for compounds 7a-1 
d were calculated in Et2O: hexane 2:1. 2 
 3 
 (1S,3R)-methyl 1-((1H-indol-3-yl)methyl)-2-(benzoylcarbamothioyl)-3-(4-4 
chlorophenyl)-5-ethyl-4,6-dioxo-octahydropyrrolo[3,4-c]pyrrole-1 5 
carboxylate (7a, C33H29ClN4O5S) 6 
Reaction time 24 h. The product crystallized from Et2O: hexane as pale-7 
yellow prisms as a 1:3 rotamer mixture. Yield 73 %; m.p.: 145-147 ºC;  Rf : 8 
0.25, 1H NMR (400 MHz, CDCl3):   = 8.55 (br s, 1H, NH, major rotamer), 9 
8.46 (br s, 1H, NH minor rotamer), 8.19-7.00 (m, 30H, Ar-H, NH major and 10 
minor), 5.63 (d, 1H, J = 11.52 Hz, 5-H minor), 5.43 (d, 1H, J = 11.2 Hz, 5-11 
H major), 4.81 (d, 2H, J= 15.44 Hz NCH2CH3 major), 4.42 (d, 2H, J= 15.04 12 
Hz NCH2CH3 minor), 3.96 (s, 3H, OCH3 major), 3.90 (s, 3H, OCH3 minor), 13 
3.20-2.99 (m, 4H, 6-H, 6-H’  major and minor), 2.77- 2.44 (m, 2H, 3-H major 14 
and minor), 1.41-1.19 (m, 5H, 4-H major and minor, CH2CH3 minor), 0.68 15 
(t, 3H, J= 7.2 Hz, CH2CH3 major) ppm; 
13C NMR (100 MHz, CDCl3): = 16 
187.3 (C=S), 178.8 (C=O), 173.8 (C=O), 173.1 (C=O), 170.2 (C=O), 135.9, 17 
135.0, 133.9, 33.6, 133.3, 133.1, 129.2 (2 C), 128.8, 128.7 (2 C), 127.8, 18 
127.6 (2 C), 124.3, 122.9 , 121.7, 120.7, 117.9, 69.0, 68.3, 53.1, 49.4, 47.8, 19 
34.0, 33.9, 12.5, 12.3 ppm; IR:  = 3374, 2981, 2946, 2925, 1782 (C=O), 20 
1740 (C=O), 1702 (C=O), 1228, 710 cm-1, MS (ESI): m/z = 627.3 ([M-H+], 21 
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100), 629.3 ([M-H+], 45), HRMS (ES): C33H29ClN4O5S calc. ([M+H]
+ 1 
628.1547, found 628.1546. 2 
 3 
1S,3R,3aS,6aR)-ethyl 1-((1H-indol-2-yl)methyl)-2-(benzoylcarbamothioyl)-4 
3-(4-methoxyphenyl)-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-5 
carboxylate (7b, C39H34N4O6S)  6 
Reaction time 24 h. The product crystallized from Et2O: hexane as pale-7 
yellow prisms as a 1:1 rotamer mixture. Yield 90 %; m.p.: 170-172 ºC; Rf : 8 
0.20, 1H NMR (400 MHz, CDCl3):   =  8.56 (br s, 1H, NH major rotamer), 9 
8.49 (br s, 1H, NH minor rotamer), 8.22-6.51 (m, 40H, Ar-H, NH major and 10 
minor), 5.57 (d, 1H, J = 11.00 Hz, 5-H minor), 5.53 (d, 1H, J = 11.32 Hz, 5-11 
H major), 4.98 (d, 1H, J = 15.4 Hz, 6-H minor), 4.48 (d, 1H, J = 15.24 Hz, 12 
6- H' minor), 4.43-4.18 (m, 4H, CH2CH3 major and minor), 3.94 (d, 1H, J = 13 
14.96 Hz, 6-H major), 3.91-3.83 (m, 2H, 4-H major and minor) 3.86 (d, 1H,  14 
J = 14.96 Hz, 6- H' major), 3.74 (s, 3H, OCH3 minor), 3.73 (s, 3H, OCH3 15 
major), 2.82 (dd, 1H, J=10.44 Hz, 10.32 Hz, 3-H major), 2.55 (dd, 1H, J= 16 
10.9 Hz, 9.04 Hz, 3-H minor), 1.43 (t, 3H, J= 6.96 Hz,  CH2CH3 major), 1.30 17 
(t, 3H, J= 7.12 Hz,  CH2CH3 minor) ppm; 
13C NMR (100 MHz, CDCl3): = 18 
187.0 (C=S major), 173.0 (C=S minor), 172.9 (C=O major), 172.6 (C=O 19 
major), 172.3 (C=O minor), 171.9 (C=O minor), 169.6 (C=O major), 167.8 20 
(C=O minor), 164.0 (C=O minor), 159.1 (C=O major), 135.9 (2 C major), 21 
MCCM_Template_Vers 4   May 2014    
 26 
133.7 (C major), 133.7 (C minor), 133.1 (C minor), 132.9 (C major), 132.7 1 
(C major), 131.7 (C major), 131.0 (C minor), 130.9 (C major), 130.2 (2 C 2 
minor), 129.2 (2 C minor), 129.0 (4 C major), 128.9 (3 C minor), 128,6 (4 C 3 
major), 128,5 (2 C minor), 127.8 (C minor), 127.7 (C minor), 127.6 (2 C 4 
minor), 127.5 (C minor), 126.7 (C minor), 125.9 (5 C major), 125.7 (C 5 
minor), 124.3 (C major),  122.8 (C major), 122.5 (C minor), 120.6 (C major), 6 
120.4 (C minor), 118,1 (C major), 117.9 (C minor), 113.9 (C minor), 113.7 7 
(C major), 111.9 (C major), 111.8 (C minor), 108.9 (C major), 108.5 (C 8 
minor), 76.1 (minor), 69.1 (C major), 68.6 (C minor), 62,1 (C major), 55.4 9 
(C major), 55.2 (2 C minor), 54.3 (C minor), 52.8 (C major), 49.5 (C minor), 10 
48.2 (C major), 33.0 (C major), 29.7 (C minor), 28.2 (C minor), 14.0 (2 C 11 
major) ppm; IR: = 3440, 2990, 1731, 1711, 1245, 1213 cm-1 , MS (ESI) 12 
m/z = 687.3 ([M-H+], 100). 13 
 14 
(1S,3R,3aS,6aR)-ethyl 1-((1H-indol-3-yl)methyl)-2-15 
(benzoylcarbamothioyl)-3-(4-chlorophenyl)-5-methyl-4,6-16 
dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (7c, C33H29ClN4O5S) 17 
Reaction time 24 h. The product crystallized from Et2O: hexane as pale-18 
yellow prisms as a 1:1 rotamer mixture. Yield 78 %; m.p.: 128-130 ºC;  Rf : 19 
0.22, 1H NMR (400 MHz, CDCl3):   =  8.61 (br s, 1H, NH, minor rotamer), 20 
8.55 (br s, 1H, NH major rotamer), 8.20 (s, 1H, NH minor), 8.18 (s, 1H, NH 21 
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major), 7.79-7.02 (m, 28H, Ar-H, major and minor ), 5.60 (d, 1H, J = 11.40, 1 
5-H minor), 5.40 (d, 1H, J = 11.08, 5-H major),4.59-4.20 (m, 8H, CH2CH3, 2 
4-H major and minor), 3.94 (d, 1H, J = 15.52, 6-H major), 3.87 (d, 1H,  J = 3 
14.36, 6-H’ minor), 3.73-3.68 (m, 2H, 3-H major and minor), 2.57 (s, 3H, 4 
NCH3 minor), 2.45 (s, 3H, NCH3 major),1.48-1.33 (m, 6H, CH2CH3  major 5 
and minor) ppm; 13C NMR (100 MHz, CDCl3): = 187.2 (C=S major),179.7 6 
(C=S minor), 174.1 (C=O minor), 173.8 (C=O major), 173.3 (C=O major), 7 
173.0 (C=O minor), 172.1 (C=O minor), 169.6 (C=O major), 169.4 (C=O 8 
minor), 164.0 (C=O major), 135.9 (C major), 135.8 (C minor), 135.4 (C 9 
major), 134.9 (C minor), 134.6 (C minor), 133.9 (C major), 133.7 (C major), 10 
133.3 (C minor), 133.1 (C major), 133.0 (C minor), 132.3 (C minor), 132.1 11 
(C major), 131.9. (C major), 129.23 (2 C minor), 129.0 (C minor), 128.7 (2 12 
C major), 128.6 (C major), 128.5 (C minor), 128.3 (C major), 128.0 (C 13 
minor),  127.8 (C minor), 127.6 (C major), 127.4 (2 C minor),  126.2 (2 C 14 
major), 126.0 (C minor), 124.4 (C major), 122.8 (C major), 122.4 (C minor), 15 
120.6 (C major), 120.3 (C minor), 117.9 (C minor), 117.8 (C major), 111.9 16 
(C major), 111.8 (C minor), 108.7 (C major), 108.1 (C minor), 76.1 (C 17 
major), 68.8 (C minor), 68.3 (C minor), 62.5 (C major), 54.1 (C major), 52.4 18 
(C  minor), 49.5 (C minor), 48.0 (C major), 36.7 (C minor), 32.9 (C major), 19 
27.70 (C minor), 24.7 (C major), 24.5 (2 C minor), 14.0 (2 C major) ppm; 20 
IR:  =3364, 3055, 2975, 2937, 1785, 1707, 1599, 1563, 1489, 1377, 1232, 21 
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1090, 745, 711 cm-1, MS (ESI): m/z = 627.2 ([M-H+], 100), 629.2 ([M-H+], 1 
42), HRMS (ES): C33H29ClN4O5S calc. ([M+H]
+ 628.1547, found 628.1544. 2 
 3 
(1S,3R,3aS,6aR)-ethyl1-((1H-indol-2-yl)methyl)-2-(benzoylcarbamothioyl)-4 
3-(4-methoxyphenyl)-5-methyl-4,6 dioxooctahydropyrrolo[3,4-c]pyrrole-1-5 
carboxylate (7d, C34H32N4O5S)  6 
Reaction time 24 h. The product crystallized from Et2O: hexane as pale-7 
yellow prisms as a 1:1 rotamer mixture. Yield 90 %; m.p.: 198-200 ºC; Rf : 8 
0.14, 1H NMR (400 MHz, CDCl3):   =  8.52 (br s, 1H, NH, major rotamer), 9 
8.47 (br s, 1H, NH minor rotamer), 8.20-7.04 (m, 30H, Ar-H, NH major and 10 
minor), 4.92 (d, 1H, J = 15.32 Hz, 5-H minor), 4.86 (d, 1H, J = 9.16 Hz, 5-11 
H major), 4.44-4.19 (m, 6H, CH2CH3, 4-H major and minor), 3.96-3.79 (m, 12 
4H, 6-H, 6-H' major and minor), 4.00 (d, 1H, J=15.16 Hz, 3-H minor), 3.86 13 
(d, 1H, J= 4.56 Hz, 3-H major), 3.76 (s, 3H, OCH3 minor), 3.73 (s, 3H, OCH3 14 
minor), 2.81 (s, 3H, NCH3 minor), 2.45 (s, 3H, NCH3 major), 1.47 (t, 3H, J= 15 
7.12 Hz, CH2CH3  major), 1.33 (t, 3H, J= 7.12 Hz, CH2CH3 minor) ppm; 
13C 16 
NMR (100 MHz, CDCl3): = 186.9 (C=S minor), 174.1 (C=S major), 173.9 17 
(C=O minor), 173.5 (C=O major), 173.2 (C=O minor), 171.8 (C=O major), 18 
169.7 (C=O major), 164.0 (C=O minor), 159.9 (C=O minor), 159.0 (C=O 19 
major), 136.9 (3mC major), 133.7 (2 C minor), 133.2 (2 C minor), 132.9 (C 20 
major), 132.7 (C minor), 129.2 (3 C major), 128.7 (4 C minor), 128.6. (C 21 
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major), 127.8 (3 C minor), 127.6 (5 C major), 125.7 (C minor),  124.3 (2 C 1 
major), 122.7 (2 C minor),  122.4 (C major), 120.6 (2 C minor), 120.4 (C 2 
major), 118.0 (C minor), 117.9 (C major), 111.8 (C major), 111.7 (C minor), 3 
108.9 (C major), 108.5 (C minor), 68.9 (C minor), 68.6 (C major), 62.3 (2 C 4 
minor), 55.3 (C major), 55.1 (C major), 54.1 (C minor), 52.7 (C major),  49.6 5 
(C minor), 48.2 (C minor), 32.9 (C major), 28.1 (C minor), 24.6 (C major), 6 
24.4 (2 C minor), 14.0 (3 C major) ppm; IR: = 3346, 2980, 1734, 1706, 7 
1246, 1210 cm-1 , MS (ESI) m/z = 625.3 ([M-H+], 100).   8 
 9 
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36. These calculations were run with ChemBio Draw program using the 1 
MM2 package at a basic level. 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
Figure Captions 13 
Figure 1. Representative examples of biologically important aroyl thiourea 14 
/ pyrrolidine and indole scaffolds. 15 
Figure 2: Red: Control, Green: DMSO group, Navy blue: 7a at 10 µM, Pink: 16 
7a at 20 µM, Turquoise: 7a at 50 µM, Purple: 7a at 100 µM 17 
Figure 3: Red: Control, Green: DMSO group, Navy blue: 6a at 10 µM, Pink: 18 
6a at 20 µM, Turquoise: 6a at 50 µM, Purple: 6a at 100 µM. 19 
Figure 4. Effect of compounds 7a and 6a on Caspase 8 and on Caspase 9 on 20 
MCF-7 cell line.  21 
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** p<0.05 vs.  DMSO 48 h. 1 
Figure 5. Effect of compounds 7a and 6a on COX2 on MCF-7 cell line. # 2 
p<0.05 vs. Control 24h. 3 
Figure 6. MM2 minimal energy calculations [36] of compounds 7b and 8.  4 
 5 
Table 1. The MIC values (μg/cm3) of the target compounds against the 6 
bacteria and M. tuberculosis H37Rv strain. 7 
 Staphyl
ococcus 
aureus 
(ATCC 
25925) 
Escherichi
a coli 
(ATCC 
25923) 
Acinetoba
cter 
baumannii 
(ATCC 
02026) 
Bacillus 
subtilis 
(ATCC 
6633) 
Aeromonas 
hydrophila 
(ATCC 
95080) 
M. 
tuberculosi
s H37Rv 
6a 125  62,5  31,25  125  31,25 62,5 
6b 62,5 62,5 31,25 125 31,25 125 
6c 250  250  125  250  250  62,5  
6d 62,5 62,5 31,25 125 31,25 125    
7a 62,5  62,5 62,5   125 15,62  7,81 
7b 62,5 62,5 31,25 125 15,62 7,81 
7c 250  250  125  125 250  3,90  
7d 62,5 62,5 31,25 125 15,62 15,62 
Ampicillin 31.25  15.62 125  0.9 31.25   
Isoniazid      0,2 and 1 
Ethambutol      5 and 10 
 8 
 9 
Figure 1 10 
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Figure 6. MM2 minimal energy calculations [36] of compounds 7b and 8.  4 
 5 
 6 
Scheme 1 7 
MCCM_Template_Vers 4   May 2014    
 38 
 1 
 2 
 3 
 4 
 5 
MCCM_Template_Vers 4   May 2014    
 39 
 1 
Graphical Abstract 2 
 3 
